Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Anaerobic Power and Salbutamol

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02255630
Recruitment Status : Completed
First Posted : October 2, 2014
Last Update Posted : November 10, 2016
Sponsor:
Collaborator:
Natural Sciences and Engineering Research Council, Canada
Information provided by (Responsible Party):
University of British Columbia

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
Athletes using inhaled β2-adrenoreceptor agonists (IBAs) win a disproportionate number of medals. However, most previous research has shown that β2 agonists do not improve exercise performance in either asthmatic or non-asthmatic athletes. Although the majority of these studies do not show an ergogenic effect, the small number of studies with extended exercise bouts (~60 minutes) do show an advantage. The investigators believe that a controlled yet sport-specific exercise protocol will elucidate this ergogenic effect. Because IBAs may have different effects on these two groups of athletes, the investigators will measure exercise performance in both female and male elite cyclists. The investigators hypothesize that athletes will perform better during a combination steady-state/sprint exercise task following salbutamol administration.

Condition or disease Intervention/treatment Phase
Ergogenic Athletic Performance Other: Cycling Exercise Not Applicable

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 20 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Basic Science
Official Title: The Effects of High-dose Salbutamol on Anaerobic Cycling Power
Study Start Date : January 2015
Actual Primary Completion Date : November 2015
Actual Study Completion Date : August 2016

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Salbutamol inhalation
Study participants will be exposed to 1600ug salbutamol 30min prior to exercise
 Other: Cycling Exercise
Experimental: Placebo inhalation
Study participants will be exposed to 1600ug salbutamol 30min prior to exercise
 Other: Cycling Exercise


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Peak Power Output [ Time Frame: peak power output of the final 30 seconds of the cycling bout will be assessed. ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   19 Years to 40 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • maximal oxygen consumption of ≥60 and ≥55 mL⋅kg-1⋅min-1 or ≥5⋅L⋅min-1 and ≥4⋅L⋅min-1 for men and women

Exclusion Criteria:

  • pregnant women
  • any history of uncontrolled respiratory or cardiac disease
  • smokers
  • diabetics
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02255630


Locations
Layout table for location information
Canada, British Columbia
University of British Columbia, Environmental Physiology Laboratory
Vancouver, British Columbia, Canada, V6T 1Z1
Sponsors and Collaborators
University of British Columbia
Natural Sciences and Engineering Research Council, Canada
Investigators
Layout table for investigator information
Principal Investigator: Michael S Koehle, MD, PhD University of British Columbia
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: University of British Columbia
ClinicalTrials.gov Identifier: NCT02255630    
Other Study ID Numbers: H14-02788
First Posted: October 2, 2014    Key Record Dates
Last Update Posted: November 10, 2016
Last Verified: November 2016
Keywords provided by University of British Columbia:
salbutamol
exercise-induced bronchoconstriction
anaerobic power